binimetinib

Phase 3

PFIZER (PFE)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Development History

Past

days

PFEPhase 2$142.7B

binimetinib Phase 2 Results Expected

binimetinib• MSS38

Jan 19

CT.gov

00%

Drug Information

Target Indication

MSS

Clinical Trial

NCT03271047

Last updated: 12/29/2025

Regulatory Approvals

EMAPending

Balimek

Treatment of unresectable or metastatic melanoma. Treatment of unresectable melanoma, with NRA Q61 mutation.

View on EMA

EMA9/20/2018

Mektovi

MelanomaBinimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Non-small cell lung cancer (NSCLC)Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.

View on EMA

Developer

PFE

PFIZER

Healthcare•North America•NASDAQ

Related Pipeline

Amoxicillin/clavulinic acidPhase 3

Bronchitis, Chronic

DVS-233 SR (desvenlafaxine sustained release )Phase 3

Major Depressive Disorder

Insulin LisproPhase 3

Diabetes Mellitus

bazedoxifene 20 mg/ conjugated estrogens 0.45 mgPhase 3

Menopause

desvenlafaxine succinate (DVS) SRPhase 3

Vasomotor Symptoms

View full pipeline